Sold as Zynrelef. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Bupivacaine; Meloxicam (sold as Zynrelef), first approved May 12, 2021, with 2 new uses approved and 2 published complete response letters.
| Smart Knee Evaluation of Exparel and Zynrelef in TKA RecoveryTotal Knee Anthroplasty · Foundation for Orthopaedic Research and Education | Phase 4 | Not yet recruiting | Oct 16, 2026 |
| Novel Extended-Release Bupivacaine Polymer for Sustained Pain Relief Following Total Knee ArthroplastyOsteoarthritis (OA) of the Knee · Henry Ford Health System | Phase 4 | Recruiting | Aug 20, 2026 |
| Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKAPeriarticular Block, Osteoarthritis (OA) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 4 | Recruiting | Feb 24, 2026 |
| ZYNRELEF vs Continuous Catheter for Pain Management Following Shoulder ArthroplastyTotal Shoulder Arthroplasty, Pain Management · Washington University School of Medicine | Phase 4 | Enrolling by invitation | Dec 12, 2025 |
| Zynrelef Versus Adductor Canal BlockKnee Osteoarthritis, Arthritis Knee · University of Miami | Phase 4 | Not yet recruiting | Oct 14, 2025 |
| Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve GastrectomyPost Operative Pain · Texas Tech University Health Sciences Center | Early phase 1 | Recruiting | Apr 5, 2024 |
| Genicular Nerve Block Versus Its Combination With Infiltration Between Popliteal Artery and Capsule of Posterior KneePostoperative Pain · Zagazig University | Not applicable | Recruiting | Jan 5, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| May 12, 2021 | ZynrelefNDA 211988 · New combination | Heron Theraps Inc | 6 | Marketed |
| Jun 26, 2020 | Zynrelef (bupivacaine and meloxicam)Nonclinical | Approved |
| Apr 30, 2019 | Bupivacaine and MeloxicamProduct Quality, Nonclinical, Center For Devices And Radiologic Health | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA